Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Dendritic cells (DC) are involved in activating, or turning-on, your body's immune system.
Your immune system helps guard your body from germs, viruses, and other threats. Although
dendritic cells are very strong, the number of them in the body is not high enough to cause a
powerful immune response; therefore, more DC are made in a laboratory with cells collected
from an individual's blood.

In this study, we will make a vaccine that we hope will educate immune cells to target the
pp65 antigen, a type of immune marker in GBM, thus resulting in what we call the pp65 DC
vaccine. Use of a vaccine that activates your immune system is a type of immunotherapy. It is
hoped that by giving the pp65 DC vaccine as a shot under the skin, the immune system will be
activated to attack tumor cells in the brain while leaving normal cells alone.

To see if the pp65 DC vaccine is effective for the treatment of GBM, subjects will be
assigned to different treatment groups. Two groups of subjects will receive the pp65 DC
vaccine and one group will receive a placebo.

Abbreviated Inclusion Criteria:

To be assessed at study enrollment prior to standard of care chemo-radiation therapy:

- Age ≥ 18 years.

- Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma)

- The tumor must have a supratentorial component.

- Must have undergone definitive surgical resection of tumor with less than
approximately 3cm x 3cm residual enhancing tumor as product of longest perpendicular
planes by MRI.

- Recovery from the effects of surgery, postoperative infection, and other
complications.

- Diagnostic contrast-enhanced MRI or CT scan of the brain preoperatively and
postoperatively.

- Karnofsky Performance Status of ≥ 70.

- Signed informed consent.

- For females of childbearing potential, negative serum pregnancy test.

- Women of childbearing potential and male participants must be willing to practice
adequate contraception throughout the study and for at least 24 weeks after the last
dose of study drug.

To be assessed prior to initiation of adjuvant TMZ:

- Must have completed RT (targeted total dose of 59.4-60.0 Gy over ≤ 7 weeks) and
concomitant TMZ (targeted dose of 75mg/m2/d for ≤ 49 days) therapy without significant
toxicity that persisted over 4 weeks.

- History & physical with neurologic examination prior to initiation of adjuvant TMZ.

- For patients receiving steroids, daily dose must be ≤ 4 mg.

- CBC with differential with adequate bone marrow function.

- Adequate renal function.

- Adequate hepatic function.

Abbreviated Exclusion Criteria:

To be verified in order to randomize subject:

- Prior invasive malignancy unless disease free for ≥ 3 years.

- Metastases detected below the tentorium or beyond the cranial vault and leptomeningeal
involvement.

- Recurrent or multifocal malignant gliomas.

- HIV, Hepatitis B, or Hepatitis C seropositive.

- Known active infection or immunosuppressive disease.

- Prior chemotherapy or radiosensitizers (including Gliadel wafers) for cancers of the
head and neck region.

- Prior radiotherapy to the head or neck, resulting in overlap of radiation fields.

- Severe, active co-morbidity.

- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception for the entire study
period.

- Pregnant or lactating women.

- Prior allergic reaction to temozolomide, GM-CSF or Td.

- Prior history of brachial neuritis or Guillain-Barré syndrome.

- Patients treated on any other therapeutic clinical protocols within 30 days prior to
study entry.

To be assessed prior to initiation of adjuvant TMZ:

- Did not start radiation therapy and temozolomide within 7 weeks of surgery.

- Progression of disease as defined by modified RANO criteria.

- More than 45 days after completion of radiation therapy and temozolomide